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that of M. pneumoniae (Table 1). The ciproﬂoxacin MICs of
0.25 mg/L for these M. amphoriforme clinical isolates con-
trasted with the ciproﬂoxacin MIC of 1.5 mg/L obtained for
the M. amphoriforme reference strain A39 with an agar dilu-
tion method [2]. Unfortunately, this strain was not available
for this difference to be checked.
As previously suggested [1], M. amphoriforme could be
easily missed and confused with M. pneumoniae by culture,
as both of them hydrolyse glucose and lack the characteris-
tic ‘fried egg’ appearance of many mycoplasmas. In conse-
quence, molecular methods were required to distinguish
them.
M. amphoriforme was previously described as an opportun-
ist that was probably pathogenic in immunodeﬁcient patients
and did not belong to the commensal respiratory ﬂora [1,3].
Its pathogenic role was reinforced by the study of its deter-
gent-insoluble structure, which was similar to the electron-
dense core of the M. pneumoniae attachment organelle
required for virulence [7]. In our study, two children had an
underlying immunodepressive disease. However, the clinical
signiﬁcance of the detection of M. amphoriforme was uncer-
tain in both cases, as the microbiological information was
incomplete, and both children recovered without receiving
an antibiotic active against mycoplasmas. In contrast, the
adult with severe sepsis was a previously healthy person
without any immunological disorder or antecedents. As no
other bacterial or viral agent was found, M. amphoriforme
could possibly be considered to be involved in his severe
infectious syndrome, which resulted in a 2-month stay in an
intensive-care unit. Unfortunately, the detection of the myco-
plasmal origin was too late for antibiotic treatment active
against mycoplasmas to be started.
In conclusion, M. amphoriforme was isolated in respiratory
specimens from three patients with respiratory tract infec-
tions, but molecular methods were required to distinguish it
from M. pneumoniae. This species was susceptible to antibiot-
ics that are generally active against mycoplasmas, and was
slightly more susceptible to ciproﬂoxacin than M. pneumoniae.
In this study, M. amphoriforme could possibly be involved in
one case of severe respiratory infection with sepsis. More-
over, to add to the epidemiological knowledge of this species
and to specify its role as a potential respiratory pathogen,
further studies on its detection in respiratory tract speci-
mens with molecular methods are needed.
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Abstract
We report the ﬁrst international spread and dissemination of
ST93-SCCmecIV (Queensland clone) methicillin-resistant Staphy-
lococcus aureus (MRSA), previously identiﬁed in communities and
hospitals in Australia. Ten highly genetically related MRSA iso-
lates and one methicillin-susceptible S. aureus (MSSA) isolate
were identiﬁed in England between 2005 and June 2008. The
demography and clinical features were typical for community-
associated-MRSA. One female with MRSA infection died from
necrotizing pneumonia. Travel between Australia and the UK,
and some onward transmission, suggested that both importation
and clonal dissemination of this strain had occurred, albeit to a
small extent. Nosocomial transmission was not detected, but we
remain vigilant for further importations and/or spread.
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In Australia, community-associated (CA) infections associated
with non-multiresistant methicillin-resistant Staphylococcus
aureus (MRSA) became a feature in the 1990s [1]. The ST93-
MRSA-SCCmecIV Panton–Valentine leukocidin (PVL)-encod-
ing ‘Queensland’ (QLD-MRSA) clone was ﬁrst detected
among isolates collected in 2000 [1,2]. The clone accounted
for 15% of MRSA isolates detected in the community [1],
and it has since spread into and within Australian hospitals
[3]. Outside of Australia, a single UK isolate from 2005 [4]
remains the only reported instance of QLD-MRSA to date.
The Health Protection Agency’s programme of enhanced
surveillance for CA and PVL-positive MRSA from 2005
onwards suggested a complex picture of importation and
spread of strains within England [4], agreeing with interna-
tional observations of strain spread and importation inﬂuenc-
ing the local molecular epidemiology of MRSA [1,4–7]. Here,
we sought to retrospectively identify and characterize
isolates belonging to the QLD-MRSA clone, examine the
disease associations, epidemiology, patient demographics
and travel associations among cases identiﬁed in England,
and examine the genetic relationship of QLD-MRSA isolates
to a UK ST93-like methicillin-susceptible S. aureus (MSSA)
isolate.
Ten MRSA isolates referred to the Staphylococcus refer-
ence unit from 2005 to June 2008 that tested positive for
lukSF-PV (PVL) only, among 14 toxin genes [4], were identi-
cal by SmaI pulsed-ﬁeld gel electrophoresis (PFGE) [4] to a
known ST93-QLD-MRSA isolate (provided by G. W. Coo-
mbs, Perth, Australia). Individuals with MRSA infection were
mostly young, and seven of ten were male (Table 1). All of
the ten MRSA-positive individuals had skin and soft tissue
infections (SSTIs); one female went on to develop necrotizing
pneumonia, and subsequently died. Nine of the ten individu-
als were community-based (e.g. presented to general practi-
tioners or accident and emergency departments, or attended
outpatient clinics), the remaining individual was an inpatient
with no known Australian connection.
The potential for strain transmission between Australia
and the UK was highlighted previously by the emergence and
subsequent success of the UK EMRSA-15, (ST22-SCCme-
cIV), clone in Australia in both community and healthcare
settings [1,3,9–11]. Travel between Australia and the UK
was a notable feature among the UK QLD-MRSA cases
detected in this study; four of the ten individuals had trav-
elled between Australia and the UK, and one of these was
linked with transmission to a close contact in the UK. An
additional case of strain spread between two individuals was
detected; neither individual had a history of foreign travel.
The individual with MSSA was a 23-year-old female with a
SSTI and no history of foreign travel. The 11 isolates (ten
MRSA and one MSSA) were referred from six geographical
regions of England and Wales, namely: Wales, North West
England, South West England, London, the West Midlands
and the North East. Three cities (including London) had
multiple referrals of isolates, including some cases with no
travel association, suggesting that some cases undetected
importation and/or local spread had occurred within England
and Wales, and although there was no evidence of spread of
QLD-MRSA within the UK healthcare system from our data,
we remain vigilant.
In addition to the PFGE data, the ten MRSA isolates were
also identical according to toxin gene proﬁling, agr (type 3),
and SCCmec type [11,12] (Table 2). Sequence typing of the
spa repeat region [13] showed near identity with isolates
that were either spa type t202 or highly related (a single
repeat unit change occurred in one isolate) (Table 2). Agar
dilution MIC determinations, according to the British Society
for Antimicrobial Chemotherapy method [14], showed that
nine of the ten MRSA isolates were susceptible to all antibi-
otics tested (except b-lactams), and the remaining isolate
was resistant to rifampicin and erythromycin (no inducible
clindamycin resistance was detected) (Table 2). The MSSA
isolate differed from the QLD-MRSA isolates only by limited
differences PFGE proﬁles (>95% similar) (Table 2) and the
lack of an intact SCCmec cassette and the mecA gene
[11,12]. PCR characterization [15] showed that all ten MRSA
isolates and the MSSA isolate harboured a temperate
PVL-encoding bacteriophage with an elongated head shape,
suggestive of either FSLT, Fsa2958, or FsaMW2. Although
the possibility cannot be excluded that the ST93-MSSA iso-
late identiﬁed herein represents a QLD-MRSA strain that has
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excised the SCCmecIVa cassette, the available SCCmec
and PVL-encoding phage data suggest that PVL-positive
QLD-MRSA emerged out of an ST93-MSSA strain already
harbouring the PVL-encoding phage.
All 11 isolates and the control strain were non-typeable
with 22/23 phages of the basic international phage-typing set
plus three of four experimental UK phages, namely 88A, 90,
and 932, at ·100 routine test dilution, mainly agreeing with
previous reports [1,2]. However, we found that all of the iso-
lates tested in this study (including the control) had consis-
tently weak reactivity for F83A from the international set
(ﬁve to ten plaques per spot), and strong reactivity (>50
plaques per spot) for an experimental UK phage, F83C [16].
Analysis of over 50 000 isolates received by the SRU between
2003 and 2008, using the F83A and F83C reactivities as a
marker for QLD-MRSA, indicated that no representatives of
the strain (either as MSSA or MRSA) were received by the
SRU before late 2005. Overall, three post-2005 MSSA isolates
were similar to that observed in this study, which indicates
that MSSA strains of this type have a limited circulation in the
TABLE 1. Patient demographics and disease presentations
Isolate
Year of
isolation Gender
Age category
(years) Category Clinical detail
Travel to
Australia
1 2005 Male 17–40 SSTI Thumb wound Yes
2 2007 Female 17–40 SSTI Recurrent boils
3 2007 Female 17–40 Necrotizing
pneumonia
History of abscess Yes
4 2007 Female <1–16 SSTI Abscess
5 2007 Male <1–16 SSTI Thigh wound Yes
6 2008 Male 17–40 SSTI Paronychia
7 2008 Male 40–60 SSTI Abscess, contactb of 8 Yes
8 2008 Male 40–60 SSTI Abscess, contactb of 7
9 2008 Male <1–16 SSTI Blisters, contactb of 10
10 2008 Male <1–16 SSTI Boils, contactb of 9
11a 2006 Female 17–40 SSTI
Four females and
seven males
Mean = 22 years,
Median = 21.5 years
SSTI, skin and soft tissue infection.
aMethicillin-susceptible Staphylococcus aureus.
bContact = Family member or other close contact.
TABLE 2. SmaI pulsed-ﬁeld gel electrophoresis banding proﬁles, molecular characteristics and antibiotic susceptibilities of
Queensland clone isolates; isolates 1–11 are shown along with a known representative (Control) of the Queensland clone (sup-
plied by G. W. Coombs)
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MLST, multilocus sequence typing; (93), inferred sequence type.
aToxin genes tested for: sea-e, seg-j, eta, etb, etd, tst, and lukSF-PV.
bMIC values in bold type denote resistance according to British Society for Antimicrobial Chemotherapy criteria.
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UK. This, together with the observation of a strong foreign
travel link, suggested that the QLD-MRSA isolates identiﬁed
in the UK were unlikely to have evolved de novo in the UK
from PVL-positive MSSA.
The demography, clinical presentations, transmissibility and
high attack rate among the ten affected individuals are in agree-
ment with data from Australia, and were typical for CA-MRSA,
supporting the notion that ST93 is a well-adapted human-asso-
ciated lineage. QLD-MRSA has proven highly successful in Aus-
tralian community and healthcare settings. Although we
observed a wide geographical distribution of the strain in the
community, the numbers identiﬁed thus far are small, and it
remains to be seen whether this apparently ﬁt strain will dis-
seminate further in UK community and/or healthcare settings,
as has been observed with other CA-MRSA strains (e.g. ST8-
SCCmecIV, USA300) in countries where the numbers of
affected individuals are higher [1,17,18]. Moreover, the high
attack rate observed underlines the necessity for enhanced
surveillance as well as vigilance for PVL-related symptoms to
assist in the interruption of clonal spread.
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